ArticleInflammopharmacology2026
Laminarin attenuates neuroinflammation in MPTP-induced Parkinson's disease mouse model via inhibiting dectin-1/Syk/NF-κB signaling.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neuroinflammation is a critical contributor to the pathogenesis of Parkinson’s disease (PD), characterized by progressive neurodegeneration of dopaminergic neurons and motor impairment. Dectin-1, a C-type lectin pattern recognition receptor (CLR), plays an important role in promoting inflammation. However, the function of Dectin‑1-mediated signaling in PD remains to be elucidated. This study aimed to investigate the neuroprotective effect of laminarin (LAM), a specific antagonist of Dectin-1, on 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced mouse model of PD. Our results showed that LAM protected against MPTP-induced motor dysfunction and dopaminergic neuronal apoptosis in a dose-dependent manner in PD mice. MPTP treatment promoted overactivation of microglia and astrocytes in the nigrostriatal pathway, which was reversed by LAM intervention. LAM significantly inhibited MPTP-induced upregulation of Dectin-1 as well as the phosphorylation of Syk and NF-κB in the substantia nigra (SN). Moreover, LAM significantly decreased the mRNA level of iNOS, TNF-α and IL-1β, and suppressed the protein expression of NLRP3, iNOS and COX-2. This study collectively suggests that Dectin-1 plays a pivotal role in MPTP-induced neuroinflammation and neuronal apoptosis. The protective effects of LAM against MPTP-induced neurotoxicity are mediated by inhibition of the Dectin-1/Syk/NF-κB signaling pathway, highlighting the Dectin-1 pathway as a potential therapeutic target for further investigation in PD.
Indexed as
Identifiers
41746595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.